Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04660929 · ClinicalTrials.gov registry record · Phase 1
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
A Phase 1 study of Breast Cancer and Cancer, sponsored by Carisma Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 7
- Study locations
NCT04660929: Active Phase 1 study of Breast Cancer and Cancer, sponsored by Carisma Therapeutics.
NCT04660929 is a Phase 1 study of Breast Cancer and Cancer that is active but no longer recruiting, run by Carisma Therapeutics. The registered enrollment target is 48 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04660929, a Phase 1 study of Breast Cancer and Cancer, is active but no longer recruiting, sponsored by Carisma Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 7
- Study locations
Study Summary
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL CT-0508
Study Locations (7)
California
- City of Hope National Medical Center - Duarte
North Carolina
- UNC Lineberger Comprehensive Cancer Center - Chapel Hill
Oregon
- OHSU Knight Cancer Institute - Portland
Pennsylvania
- Abramson Cancer Center - Philadelphia
Tennessee
- Tennessee Oncology / Sarah Cannon Research Institute - Nashville
Texas
- M D Anderson Cancer Center - Houston
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-02-02 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 1 |
What the registry record for NCT04660929 still lists
NCT04660929 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04660929 lists 7 locations in 7 states (California, North Carolina, Oregon).
Frequently Asked Questions
What is clinical trial NCT04660929 about?
NCT04660929 is a clinical study titled "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors". Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
What is the current status of trial NCT04660929?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2021-02-02. Estimated completion is 2024-12-31.
What conditions does trial NCT04660929 study?
This clinical trial studies the following conditions: Breast Cancer, Cancer, Bladder Cancer, Biliary Tract Cancer, Carcinoma, Hepatocellular.
What interventions are being tested in trial NCT04660929?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), CT-0508 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04660929?
This trial is sponsored by Carisma Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04660929 being conducted?
This trial has 7 study locations across California, North Carolina, Oregon, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04660929's enrollment target sits among peer trials
48 821st of 1224 higher than 394 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI